Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, announced today that the Broad Institute of MIT and Harvard has joined the Caris Precision Oncology Alliance™ (POA). As a POA member, the Broad Institute will collaborate with Caris on various precision oncology research projects and signature development.
The POA is a growing network of leading cancer centers and research consortia across the globe that collaborate to advance precision oncology and biomarker-driven research, with its members working together to establish and optimize standards of care for molecular testing through innovative research to improve clinical outcomes for cancer patients. POA members are uniquely positioned to leverage Caris’ highly sophisticated AI bioinformatics and machine learning capabilities across the company’s massive clinico-genomic database to enable innovative research to improve clinical outcomes for cancer patients.
The Broad Institute of MIT and Harvard is an independent, nonprofit research organization that convenes a community of researchers from across many disciplines from the MIT, Harvard, and Harvard-affiliated hospital community.
“We’re thrilled to welcome the Broad Institute to the Caris POA. Their inclusion in Caris’ extensive network is a further testament to our commitment to precision oncology research through collaboration with institutions executing on cutting edge ideas,” said David Dean Halbert, DSc (h.c.), Chairman, Founder and CEO of Caris. “The Caris POA and the Broad Institute share a vision of improving the outcomes of all patients affected with cancer.”
The Caris Precision Oncology Alliance includes 86 cancer centers, academic institutions, research consortia and healthcare systems. These institutions have early access to the extensive database and artificial intelligence platform within Caris to establish evidence-based standards for cancer profiling and molecular testing in oncology. By leveraging the comprehensive genomic, transcriptomic and proteomic profiling available through Caris molecular profiling, Caris seeks to provide this network with the ability to prioritize therapeutic options and determine which clinical trial opportunities may benefit their patients. POA members are also able to integrate with a growing portfolio of biomarker-directed trials sponsored by biopharma. Additionally, POA member institutions have access to the most comprehensive clinico-genomic database in the industry, which includes matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, covering over 1 million data points per patient.
